miR-370、Bmi-1、Nrf2在肺癌中的表达及其与临床病理特征的相关性
|
摘要
目的分析微小核糖核酸-370(miR-370)、B细胞特异性莫洛氏鼠白血病病毒插入位点1(Bmi-1)、核转录相关因子-2(Nrf2)在肺癌中的表达及其与患者临床病理特征的关系。方法选择我院收治的73例肺癌患者的癌组织标本,并保留同期38例肺癌患者距肿瘤边缘5 cm的癌旁组织标本。比较miR-370、Bmi-1、Nrf2在肺癌组织及癌旁组织中的表达情况,分析miR-370、Bmi-1、Nrf2表达与肺癌临床病理特征及预后的关系。结果肺癌组织miR-370高表达率低于癌旁组织,Bmi-1、Nrf2阳性表达率高于癌旁组织,差异均有统计学意义(P<0.05)。miR-370、Bmi-1、Nrf2表达在不同性别、年龄、肿瘤大小及细胞分型中的差异无统计学意义(P>0.05),在淋巴结转移、TNM分期中的差异有统计学意义(P<0.05)。miR-370高表达患者生存率明显高于低表达患者,Bmi-1、Nrf2阳性表达患者生存率明显低于阴性表达患者(P<0.05)。COX回归模型分析显示,淋巴结转移、TNM分期、Bmi-1及Nrf2是影响预后的危险因素,miR-370是保护因素。结论 miR-370、Bmi-1、Nrf2表达与肺癌患者临床病理特征相关,能够反映肿瘤的恶性生物学行为,可作为肺癌患者预后评估的参考指标。
Objective To analyze the expression of microribonucleic acid-370(miR-370), B-cell-specific Moloney murine leukemia virus insertion site 1(Bmi-1) and nuclear transcription-related factor-2(Nrf2) in lung cancer and their correlation with the clinical and pathological characteristics of patients. Methods Cancer tissue specimens from 73 lung cancer patients in our hospital were selected in this study. And the paracancerous tissue specimens 5 cm away from the tumor edge of 38 lung cancer patients were retained in the same period.The expressions of miR-370, Bmi-1 and Nrf2 in lung cancer tissues and paracancerous tissues were compared, and the relationship between the expressions of miR-370, Bmi-1 and Nrf2 and the clinicopathological characteristics and prognosis of lung cancer was analyzed. Results The high expression rate of miR-370 in lung cancer tissues was lower than in the adjacent tissues, and the positive expression rates of Bmi-1 and Nrf2 were higher in lung cancer tissues than in the adjacent tissues(P<0.05). The high expression rate of mir-370 and the positive expression rate of Bmi-1 and Nrf2 showed no statistical differences between different genders, ages, tumor sizes and cell types(P>0.05). But they showed statistically significant differences between different groups of lymph node metastasis, TNM staging and differentiation degree(P<0.05). The patients with high expression of miR-370 had higher survival rate than those with low expression of miR-370, and patients with Bmi-1 and Nrf2 positive expression had lower survival rate than those with negative expression(P<0.05). COX regression model analysis showed that lymph node metastasis, TNM stage, Bmi-1 and Nrf2 were risk factors for prognosis, while miR-370 was a protective factor.Conclusion The expressions of miR-370, Bmi-1 and Nrf2 are correlated with the clinicopathological characteristics of lung cancer patients.The miR-370, Bmi-1 and Nrf2 could reflect the malignant biological behavior of tumors, so that could be used as a reference index for the prognosis evaluation of lung cancer patients.
Objective To analyze the expression of microribonucleic acid-370(miR-370), B-cell-specific Moloney murine leukemia virus insertion site 1(Bmi-1) and nuclear transcription-related factor-2(Nrf2) in lung cancer and their correlation with the clinical and pathological characteristics of patients. Methods Cancer tissue specimens from 73 lung cancer patients in our hospital were selected in this study. And the paracancerous tissue specimens 5 cm away from the tumor edge of 38 lung cancer patients were retained in the same period.The expressions of miR-370, Bmi-1 and Nrf2 in lung cancer tissues and paracancerous tissues were compared, and the relationship between the expressions of miR-370, Bmi-1 and Nrf2 and the clinicopathological characteristics and prognosis of lung cancer was analyzed. Results The high expression rate of miR-370 in lung cancer tissues was lower than in the adjacent tissues, and the positive expression rates of Bmi-1 and Nrf2 were higher in lung cancer tissues than in the adjacent tissues(P<0.05). The high expression rate of mir-370 and the positive expression rate of Bmi-1 and Nrf2 showed no statistical differences between different genders, ages, tumor sizes and cell types(P>0.05). But they showed statistically significant differences between different groups of lymph node metastasis, TNM staging and differentiation degree(P<0.05). The patients with high expression of miR-370 had higher survival rate than those with low expression of miR-370, and patients with Bmi-1 and Nrf2 positive expression had lower survival rate than those with negative expression(P<0.05). COX regression model analysis showed that lymph node metastasis, TNM stage, Bmi-1 and Nrf2 were risk factors for prognosis, while miR-370 was a protective factor.Conclusion The expressions of miR-370, Bmi-1 and Nrf2 are correlated with the clinicopathological characteristics of lung cancer patients.The miR-370, Bmi-1 and Nrf2 could reflect the malignant biological behavior of tumors, so that could be used as a reference index for the prognosis evaluation of lung cancer patients.
引文
[1]Brunnstr?m H, Johansson A, Westbom-Fremer S, et al.PD-L1 immunohistochemistry in clinical diagnostics of lung cancer:inter-pathologist variability is higher than assay variability[J]. Mod Pathol, 2017, 30(10):1411-1421. doi:10.1038/modpathol.2017.59.
[2]Mathew A, Sara George P, M C K, et al. Cancer Incidence and Mortality:District Cancer Registry, Trivandrum,South India[J]. Asian Pac J Cancer Prev, 2017, 18(6):1485-1491. doi:10.22034/APJCP.2017.18.6.1485.
[3]Mariampillai AI, Cruz JPD, Suh J, et al. Cancer Antigen 72-4for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries[J]. Anticancer Res, 2017, 37(7):3649-3656. doi:10.21873/anticanres.11735.
[4]Amin NP, Mohindra P, Jabbour SK. Serum microRNA guiding personalized radiation therapy in non-small cell lung cancer[J]. J Thorac Dis, 2018, 10(Suppl 33):S4108-S4112. doi:10.21037/jtd.2018.09.143.
[5]刘德纲,彭江州,李军,等.肺癌组织中Notch1、Bmi-1蛋白的表达变化及其意义[J].山东医药, 2017, 57(23):58-60. doi:10.3969/j. issn.1002-266X.2017.23.017.
[6]杨晓霞,孙世仁. Bmi-1基因研究进展[J].医学综述, 2016, 22(5):890-892, 903. doi:10.3969/j. issn.1006-2084.2016.05.016.
[7]周天域,吕鑫,陈雨桐,等. Nrf2的代谢调节作用与肿瘤的生长和增殖[J].中国细胞生物学学报, 2017, 39(03):132-139. doi:10.11844/cjcb.2017.03.0291.
[8]丁颖威,卢中秋. NRF2与肺部疾病的关系研究进展[J].医学研究杂志, 2016, 45(10):159-161. doi:10.11969/j.issn.1673-548X.2016.10.042.
[9]Boldrini L, Giordano M, Lucchi M, et al. Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients[J]. Biomed Rep,2018, 9(3):198-205. doi:10.3892/br.2018.1122.
[10]刘勇,杨海玉.国际特设专家委员会建议:诊断免疫组化阳性对照标准化[J].临床与实验病理学杂志, 2016,32(1):1-3. doi:10.13315/j. cnki. cjcep.2016.01.001.
[11]Mohan A, Poulose R, Gupta T, et al. Impact of chemotherapy on symptom profile, oxidant-antioxidant balance and nutritional status in non-small cell Lung Cancer[J]. Lung India,2017, 34(4):336-340. doi:10.4103/0970-2113.209230.
[12]Motooka Y, Fujino K, Sato Y, et al. Pathobiology of Notch2in lung cancer[J]. Pathology, 2017, 49(5):486-493. doi:10.1016/j. pathol.2017.05.005.
[13]刘婕,万晓春,吕卫东,等. miRNA在防治非小细胞肺癌中的研究进展[J].现代生物医学进展, 2015, 15(10):1966-1970. doi:10.13241/j. cnki. pmb.2015.10.044.
[14]Yu H, Guan Z, Cuk K, et al. Circulating microRNA biomarkers for lung cancer detection in Western populations[J]. Cancer Med, 2018, 7(10):4849-4862. doi:10.1002/cam4.1782.
[15]刘馨,兰敏,陈晓群,等. miR-370和EGFR在肺癌中的表达及其临床意义[J].中国肿瘤生物治疗杂志, 2018, 25(1):94-97. doi:10.3872/j. issn.1007-385x.2018.01.017.
[16]兰敏,陈艳,王熙才. miR-370在肿瘤中的作用及其机制[J].中国肿瘤生物治疗杂志, 2016, 23(2):291-296. doi:10.3872/j. issn.1007-385X.2016.02.023.
[17]张庆华,徐彪,任玉波,等. p16与Bmi-1基因在非小细胞肺癌中的表达及与临床病理特征的关系[J].实用医学杂志, 2015, 31(13):2158-2161. doi:10.3969/j. issn.1006-5725.2015.13.028.
[18]蔡华荣,江跃全. Notch1和Bmi-1蛋白在肺癌组织中的表达及意义[J].中国组织工程研究, 2016, 20(5):683-687. doi:10.3969/j. issn.2095-4344.2016.05.013.
[19]张轩斌,金博,彭飞,等.沉默Bmi-1表达对人小细胞肺癌细胞凋亡的影响及其机制研究[J].临床肺科杂志, 2018,23(06):62-66. doi:10.3969/j. issn.1009-6663.2018.06.016.
[20]肖宇,朱翔,顾阳春,等. Nrf2、Keap1蛋白在104例肺腺癌中的表达及其临床病理特征[J].中国肺癌杂志, 2018, 21(3):241-250. doi:10.3779/j. issn.1009-3419.2018.03.04.
[21]周建平,李志芳,梁笠轩,等.肺癌细胞系中KEAP1与NRF2相互作用区域基因突变的检测[J].重庆医学, 2017,46(5):590-592. doi:10.3969/j. issn.1671-8348.2017.05.005.
[22]冯稳,张冰,于庆凯.核因子E2相关因子2在肺腺癌中的表达及临床意义[J].中国现代医学杂志, 2016, 26(4):29-32. doi:10.3969/j. issn.1005-8982.2016.04.006.
[2]Mathew A, Sara George P, M C K, et al. Cancer Incidence and Mortality:District Cancer Registry, Trivandrum,South India[J]. Asian Pac J Cancer Prev, 2017, 18(6):1485-1491. doi:10.22034/APJCP.2017.18.6.1485.
[3]Mariampillai AI, Cruz JPD, Suh J, et al. Cancer Antigen 72-4for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries[J]. Anticancer Res, 2017, 37(7):3649-3656. doi:10.21873/anticanres.11735.
[4]Amin NP, Mohindra P, Jabbour SK. Serum microRNA guiding personalized radiation therapy in non-small cell lung cancer[J]. J Thorac Dis, 2018, 10(Suppl 33):S4108-S4112. doi:10.21037/jtd.2018.09.143.
[5]刘德纲,彭江州,李军,等.肺癌组织中Notch1、Bmi-1蛋白的表达变化及其意义[J].山东医药, 2017, 57(23):58-60. doi:10.3969/j. issn.1002-266X.2017.23.017.
[6]杨晓霞,孙世仁. Bmi-1基因研究进展[J].医学综述, 2016, 22(5):890-892, 903. doi:10.3969/j. issn.1006-2084.2016.05.016.
[7]周天域,吕鑫,陈雨桐,等. Nrf2的代谢调节作用与肿瘤的生长和增殖[J].中国细胞生物学学报, 2017, 39(03):132-139. doi:10.11844/cjcb.2017.03.0291.
[8]丁颖威,卢中秋. NRF2与肺部疾病的关系研究进展[J].医学研究杂志, 2016, 45(10):159-161. doi:10.11969/j.issn.1673-548X.2016.10.042.
[9]Boldrini L, Giordano M, Lucchi M, et al. Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients[J]. Biomed Rep,2018, 9(3):198-205. doi:10.3892/br.2018.1122.
[10]刘勇,杨海玉.国际特设专家委员会建议:诊断免疫组化阳性对照标准化[J].临床与实验病理学杂志, 2016,32(1):1-3. doi:10.13315/j. cnki. cjcep.2016.01.001.
[11]Mohan A, Poulose R, Gupta T, et al. Impact of chemotherapy on symptom profile, oxidant-antioxidant balance and nutritional status in non-small cell Lung Cancer[J]. Lung India,2017, 34(4):336-340. doi:10.4103/0970-2113.209230.
[12]Motooka Y, Fujino K, Sato Y, et al. Pathobiology of Notch2in lung cancer[J]. Pathology, 2017, 49(5):486-493. doi:10.1016/j. pathol.2017.05.005.
[13]刘婕,万晓春,吕卫东,等. miRNA在防治非小细胞肺癌中的研究进展[J].现代生物医学进展, 2015, 15(10):1966-1970. doi:10.13241/j. cnki. pmb.2015.10.044.
[14]Yu H, Guan Z, Cuk K, et al. Circulating microRNA biomarkers for lung cancer detection in Western populations[J]. Cancer Med, 2018, 7(10):4849-4862. doi:10.1002/cam4.1782.
[15]刘馨,兰敏,陈晓群,等. miR-370和EGFR在肺癌中的表达及其临床意义[J].中国肿瘤生物治疗杂志, 2018, 25(1):94-97. doi:10.3872/j. issn.1007-385x.2018.01.017.
[16]兰敏,陈艳,王熙才. miR-370在肿瘤中的作用及其机制[J].中国肿瘤生物治疗杂志, 2016, 23(2):291-296. doi:10.3872/j. issn.1007-385X.2016.02.023.
[17]张庆华,徐彪,任玉波,等. p16与Bmi-1基因在非小细胞肺癌中的表达及与临床病理特征的关系[J].实用医学杂志, 2015, 31(13):2158-2161. doi:10.3969/j. issn.1006-5725.2015.13.028.
[18]蔡华荣,江跃全. Notch1和Bmi-1蛋白在肺癌组织中的表达及意义[J].中国组织工程研究, 2016, 20(5):683-687. doi:10.3969/j. issn.2095-4344.2016.05.013.
[19]张轩斌,金博,彭飞,等.沉默Bmi-1表达对人小细胞肺癌细胞凋亡的影响及其机制研究[J].临床肺科杂志, 2018,23(06):62-66. doi:10.3969/j. issn.1009-6663.2018.06.016.
[20]肖宇,朱翔,顾阳春,等. Nrf2、Keap1蛋白在104例肺腺癌中的表达及其临床病理特征[J].中国肺癌杂志, 2018, 21(3):241-250. doi:10.3779/j. issn.1009-3419.2018.03.04.
[21]周建平,李志芳,梁笠轩,等.肺癌细胞系中KEAP1与NRF2相互作用区域基因突变的检测[J].重庆医学, 2017,46(5):590-592. doi:10.3969/j. issn.1671-8348.2017.05.005.
[22]冯稳,张冰,于庆凯.核因子E2相关因子2在肺腺癌中的表达及临床意义[J].中国现代医学杂志, 2016, 26(4):29-32. doi:10.3969/j. issn.1005-8982.2016.04.006.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |